EPS for Clovis Oncology, Inc. (CLVS) Expected At $-1.71

October 14, 2018 - By Winifred Garcia

Clovis Oncology, Inc. (NASDAQ:CLVS) LogoInvestors sentiment increased to 1.17 in Q2 2018. Its up 0.12, from 1.05 in 2018Q1. It increased, as 33 investors sold Clovis Oncology, Inc. shares while 48 reduced holdings. 25 funds opened positions while 70 raised stakes. 52.83 million shares or 9.43% more from 48.28 million shares in 2018Q1 were reported.
Fifth Third National Bank & Trust accumulated 89 shares. State Street invested in 0.01% or 2.47 million shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 2,595 shares. Tocqueville Asset Management L P holds 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 5,400 shares. Jpmorgan Chase Com reported 243,488 shares. Raymond James Financial Advsr owns 21,159 shares or 0% of their US portfolio. Carmignac Gestion, France-based fund reported 1.52 million shares. California State Teachers Retirement Systems holds 72,868 shares. Venbio Select Advisor Ltd Co reported 1.15M shares. Germany-based Deutsche Bancorporation Ag has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Metropolitan Life Ins Com New York owns 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 15,513 shares. The New York-based Focused Wealth has invested 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS). Essex Inv Company Limited Liability Corp owns 15,383 shares or 0.09% of their US portfolio. Opus Point Management Limited Liability Corporation has invested 1.28% in Clovis Oncology, Inc. (NASDAQ:CLVS). Fred Alger Mngmt Inc invested in 172,356 shares or 0.03% of the stock.

Analysts expect Clovis Oncology, Inc. (NASDAQ:CLVS) to report $-1.71 EPS on November, 7.They anticipate $0.47 EPS change or 37.90 % from last quarter’s $-1.24 EPS. After having $-1.94 EPS previously, Clovis Oncology, Inc.’s analysts see -11.86 % EPS growth. The stock decreased 4.26% or $1.19 during the last trading session, reaching $26.73. About 1.30M shares traded or 15.54% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 53.53% since October 14, 2017 and is downtrending. It has underperformed by 69.15% the S&P500.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Among 2 analysts covering Clovis Oncology (NASDAQ:CLVS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Clovis Oncology had 2 analyst reports since June 10, 2018 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $7300 target in Sunday, June 10 report.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $1.41 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

More recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Streetinsider.com which released: “Pre-Open Movers 10/02: (DTEA) (OMER) (CLVS) Higher; (SFIX) (NBEV) (VNE) Lower (more…)” on October 02, 2018. Also Seekingalpha.com published the news titled: “Clovis Oncology: Some Positives Emerge” on October 03, 2018. Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: October 12, 2018 was also an interesting one.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>